Novartis receives European Commission approval for Itvisma(R) for spinal muscular atrophy (SMA)
DO Dow Jones Newswires Novartis receives European Commission approval for Itvisma(R) for spinal muscular atrophy (SMA) 7/2/2026, 01:00 PM GMT+8 Dow Jones Newswires NO NOVN Novartis receives European Commission approval for Itvisma(R) for spinal muscular atrophy (SMA) Market News Zacks NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population dpa-AFX Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal Dow Jones Newswires Novartis Gets European Commission Approval for Spinal Muscular Atrophy Treatment Reuters Novartis Receives European Commission Approval For Itvisma® For Spinal Muscular Atrophy (SMA)
